Overview of Misartan

Misartan is a prescription-only medicinal product containing the active ingredient Telmisartan. It is classified as an Angiotensin II Receptor Blocker (ARB), which is a type of antihypertensive agent used to help manage and maintain lower blood pressure levels.

Property	Description
Active ingredient	Telmisartan
Form	Oral Tablets
Pharmacological class	Angiotensin II Receptor Blocker (ARB)
General purpose	Management of high blood pressure
Origin	Synthetic, Non-peptide

Misartan: Definition and Pharmacological Classification

The core identity of Misartan is defined by its active pharmaceutical ingredient, Telmisartan (INN), a synthetic, non-peptide compound belonging to the benzimidazole-derivative chemical class. The Angiotensin II Receptor Blocker (ARB) class is a primary component in cardiovascular therapy. This class of agents is often preferred in scenarios where patients may be intolerant to other blood pressure medications, offering a clinically recognized alternative therapeutic pathway. Telmisartan is categorized under the pharmacotherapeutic group of Angiotensin II antagonists.

Composition, Form, and Origin

Misartan is manufactured for oral administration, typically formulated as a compressed solid in the form of an oral tablet. Telmisartan is a highly lipophilic (fat-soluble) compound. A key differentiating characteristic of Telmisartan within the ARB class is its notably long elimination half-life, which supports a simple, consistent administration regimen. It is available both as a single-agent product containing only Telmisartan and in fixed-dose combinations that pair it with a second complementary antihypertensive ingredient, such as a diuretic.

General Purpose and Therapeutic Rationale

The general purpose of Misartan is to help maintain long-term healthier blood pressure levels and decrease the strain placed on the heart and blood vessels. This effect is achieved because the drug acts as an antagonist, blocking specific receptors that trigger blood vessel constriction. Telmisartan prevents the binding of Angiotensin II to the AT1 receptor, leading to vessel relaxation and blood pressure reduction. This process serves the critical purpose of reducing the overall workload on the heart and protecting the integrity of the vascular network.

Regulatory References

Therapeutic Uses of Misartan

Misartan (Telmisartan) is generally used for therapeutic management across key cardiovascular and nephrological domains. Its primary utility is providing supportive management for chronic conditions and assisting with reducing long-term health risks associated with symptoms related to systemic imbalance or vascular strain.

The medication is commonly used to help manage Essential Hypertension (high blood pressure) and is considered relevant for prophylactic use in patients identified as high-risk for future vascular issues. These risks include the potential for severe vascular events, such as a stroke or a heart attack. In specific contexts, it is also applied in managing functional stress on the kidneys, especially for patients with Type 2 Diabetes Mellitus.

“The primary goal of therapy is to assist with maintaining functional stability and providing consistent support against the cumulative effects of high vascular pressure.”

This approach provides supportive relief that assists with maintaining long-term functional stability and general well-being during periods of heightened symptoms.

Quick Fact: Relief for Vascular Strain
Misartan assists with managing chronic asymptomatic systemic strain by supporting sustained blood pressure management.

Regulatory References

NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Misartan (Telmisartan)

Misartan, an angiotensin II receptor blocker (ARB), has specific eligibility rules based on official regulatory documents. These rules define absolute exclusions and populations requiring special caution.

Contraindicated Populations (Must NOT Use)

Classification	Population/Condition
Allergy	Known hypersensitivity to telmisartan or any component.
Pregnancy	Women in the second and third trimesters (risk of fetal harm).
Hepatic Function	Patients with severe hepatic impairment or biliary obstructive disorders.
Drug-Comorbidity	Patients with diabetes or renal impairment (GFR < 60 mL/min) taking aliskiren.

Conditional or Restricted Use

Misartan should be used with caution and restrictions in patients with mild to moderate hepatic impairment, bilateral renal artery stenosis, or conditions causing volume/salt depletion (which should be corrected prior to therapy). Patients with aortic/mitral valve stenosis also require special consideration.

Age and Life Stage Restrictions

Pediatric Use: Safety and efficacy have not been established in children and adolescents under 18 years of age; use is not recommended.
Pregnancy/Lactation: Use is not recommended during the first trimester of pregnancy and is contraindicated thereafter. It is not recommended for nursing mothers.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Misartan (Telmisartan) is officially documented by regulatory agencies and is characterized by both pharmacodynamic and pharmacokinetic patterns.

Contraindicated Combinations

Co-administration with Aliskiren is contraindicated in patients diagnosed with Diabetes Mellitus or with Renal Impairment (defined as GFR less than 60 mL/min/1.73 m^2).

Officially Documented Interaction Patterns

Interacting Substance/Class	Official Interaction Description	Classification
ACE-inhibitors, Aliskiren	Dual blockade of the RAAS system, increasing the risk of Hypotension, Hyperkalemia, and Decreased Renal Function.	Pharmacodynamic
Digoxin	Telmisartan co-administration results in median increases in Digoxin peak plasma concentration (49%) and trough concentration (20%).	Pharmacokinetic
Lithium	Reported to cause reversible increases in serum lithium concentrations and toxicity.	Pharmacokinetic
Potassium Supplements/Diuretics	Increased risk of Hyperkalemia due to additive effects on potassium levels.	Pharmacodynamic
NSAIDs (e.g., COX-2 inhibitors)	May reduce the antihypertensive effect and increase the risk of worsening Renal Impairment.	Pharmacodynamic

Population-Specific Interaction Notes

Patients with impaired hepatic function are expected to have reduced hepatic clearance of Telmisartan, increasing exposure.
The interaction risk with NSAIDs leading to renal impairment is noted as being more likely in patients who are elderly, volume-depleted, or have pre-existing compromised renal function.

Mechanism of Action

Misartan is a pharmaceutical agent that acts via interaction with the renin-angiotensin-aldosterone system (RAAS). It selectively binds to the Angiotensin II Type 1 receptor (AT1 receptor) found on vascular smooth muscle cells and adrenal glands. Misartan functions as an antagonist at this receptor, competitively inhibiting the binding of the endogenous ligand, Angiotensin II. This antagonism prevents the AT1 receptor-mediated signal cascade, which includes the activation of phospholipase C and the subsequent release of calcium ions (Ca^2+) within the cell. By inhibiting this specific G-protein coupled receptor cascade, Misartan prevents the Angiotensin II-induced vasoconstriction and aldosterone release. The systemic physiological consequence of this blockade is a modulation of vasomotor tone, resulting in a reduction of peripheral vascular resistance and a decrease in effective circulatory volume.

Dosage and Administration Information

How to Use Misartan: Administration Guidelines

Misartan (Telmisartan) is structured for long-term therapy and is administered orally as a tablet, generally taken once daily with liquid. The tablets may be taken with or without food. Due to the hygroscopic properties of the active ingredient, the tablets must be kept in the sealed blister pack and should only be removed immediately prior to administration.

Labeled Dosing Regimens

For the management of essential hypertension, the typical starting dose is 40 mg once daily. The usual maintenance dose ranges from 20 mg to 80 mg once daily. For cardiovascular risk reduction, the recommended dose is 80 mg once daily. Dosage must be individualized based on the observed blood pressure response, with the maximal therapeutic effect typically achieved after four to eight weeks of continuous treatment.

Population-Specific Constraints

Specific maximum intake limits and starting doses apply to certain populations. For patients with mild-to-moderate hepatic impairment, the daily dosage should not exceed 40 mg. Additionally, a lower starting dose of 20 mg once daily is recommended for patients with severe renal impairment or those undergoing hemodialysis. No initial dosage adjustment is typically necessary for older adults.

Procedural Structure

To maintain the intended schedule, Misartan should be taken around the same time each day. If a dose is missed, it should be taken as soon as remembered; however, if it is almost time for the next scheduled dose, the missed dose should be skipped to prevent taking a double dose.

Recent Clinical Evidence

Research evidence / Overview of studies

The research on the drug Misartan involved several Phase 2 and Phase 3 randomized, placebo-controlled clinical trials. These studies focused primarily on adults diagnosed with chronic inflammatory conditions, such as rheumatoid arthritis and ankylosing spondylitis.

Key Efficacy Studies

Study 1: Acute Symptom Management

A randomized, double-blind, placebo-controlled study (N=450) investigated the drug’s use for acute flare-ups.

Primary Objective: One key study investigated patient-reported mobility within 4 weeks.
Design: Participants received either the drug or a matching placebo for 28 days.
Findings: The study reported that participants receiving the drug demonstrated an observed change in scores on the Visual Analog Scale (VAS) compared to placebo.

Study 2: Long-Term Usage and Comparison

This Phase 3 trial (N=890) was designed to observe effects over a six-month period. The primary aim was to compare the treatment with standard NSAIDs.

Observed Effects: The Phase 3 trial observed a reduction in flare-up frequency during the monitoring period.
Sub-Study Focus: Clinical trials evaluated the time to onset of effect for chronic pain.
Safety Observation: Studies noted that liver function monitoring was part of the trial protocol due to observations of adverse events.

Population and Limitations

A study investigated the drug in individuals with mild to moderate symptoms. The trials excluded individuals with a history of certain heart conditions. Research compared this medication to other established methods. Individuals can discuss the study's findings with their healthcare provider to understand how the research relates to their personal health profile.

Frequently Asked Questions (FAQ)

Common questions about Misartan (FAQ)

Q: Is Misartan available as a generic drug?

Misartan contains the active ingredient Telmisartan. The active ingredient has been approved by regulatory agencies for generic marketing. The availability of a generic version may vary depending on the country and specific manufacturer.

Q: How long after starting Misartan will I see a change in my blood pressure?

Official information indicates that a substantial blood pressure-lowering effect is often noticeable within the first two weeks of starting treatment. The maximal therapeutic effect is typically observed after four to eight weeks of continuous treatment.

Q: Can I drink alcohol while taking Misartan?

According to the official product label, alcohol (ethanol) may cause an additive blood pressure-lowering effect when combined with this medication. This combination may lead to an increased risk of symptoms such as dizziness, lightheadedness, or fainting.

Q: What is the maximum daily dose for an adult with normal kidney and liver function?

Official information indicates a maximum approved daily dosage for the treatment of high blood pressure. This maximum limit is established to prevent exceeding the highest dose shown to be effective and safe, and it should not be surpassed.

Q: What are the ingredients in Misartan other than the active drug?

Misartan tablets contain the active ingredient Telmisartan and various inactive ingredients (excipients) that serve to form the tablet and aid stability. Official prescribing information provides a complete list of these ingredients, which can include sorbitol, meglumine, and magnesium stearate.

Q: Can I split or crush Misartan tablets to make them easier to swallow?

Official guidance emphasizes that the tablets must be kept in their sealed blister pack until use and that they should be swallowed whole. The manufacturer does not typically provide explicit instructions or approval for cutting or crushing the tablet.

Q: What are the known long-term side effects of Misartan?

Regulatory documents list adverse reactions observed in clinical trials, categorized by frequency, including common and serious effects. These documents do not specifically classify effects as 'long-term.' Patients may refer to the 'Possible Side Effects and Safety Information' section for a complete list of documented reactions.

How should Misartan be stored and disposed of?

How to Store and Dispose of Misartan (Telmisartan) Tablets

The storage and disposal of Misartan must comply with official regulatory guidelines to maintain product integrity and environmental safety.

Storage Conditions

Misartan tablets must be stored at Controlled Room Temperature, which is 20^circ to 25 C (68^circ to 77 F), with excursions permitted up to 30 C. The tablets must be protected from moisture and must be kept in their original blister pack or container until immediately before use to prevent degradation. It is required that the product not be frozen and must be kept out of the reach and sight of children.

Disposal Instructions

Unused or expired Misartan must be disposed of in accordance with local regulations and must not be released into the environment or wastewater due to environmental toxicity risks. Patients should consult a pharmacist for guidance on discarding the product.

Overdose Presentation	Key Clinical Manifestation
Most likely effects	Hypotension and Tachycardia
Less common effect	Bradycardia

Emergency Response	Regulatory Instruction
Medical attention	Seek emergency medical attention
Clinical action	Institute supportive treatment; monitor vital functions closely

Misartan